Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 5851 AL 5865

Hsp90 modulation for the treatment of Alzheimer's disease

Zhao H, Michaelis ML, Blagg BS.

Adv Pharmacol. 2012;64:1-25. doi: 10.1016/B978-0-12-394816-8.00001-5.

Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention

Silva DF, Selfridge JE, Lu J, E L, Cardoso SM, Swerdlow RH.

Adv Pharmacol. 2012;64:83-126. doi: 10.1016/B978-0-12-394816-8.00003-9.

γ-Secretase as a target for Alzheimer's disease

Wolfe MS.

Adv Pharmacol. 2012;64:127-53. doi: 10.1016/B978-0-12-394816-8.00004-0.

scyllo-Inositol, preclinical, and clinical data for Alzheimer's disease

Ma K, Thomason LA, McLaurin J.

Adv Pharmacol. 2012;64:177-212. doi: 10.1016/B978-0-12-394816-8.00006-4.

Beyond amyloid: the future of therapeutics for Alzheimer's disease

Lane RF, Shineman DW, Steele JW, Lee LB, Fillit HM.

Adv Pharmacol. 2012;64:213-71. doi: 10.1016/B978-0-12-394816-8.00007-6.

Striatal-enriched protein tyrosine phosphatase in Alzheimer's disease

Xu J, Kurup P, Nairn AC, Lombroso PJ.

Adv Pharmacol. 2012;64:303-25. doi: 10.1016/B978-0-12-394816-8.00009-X.

Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients

Martorana A, Di Lorenzo F, Esposito Z, Lo Giudice T, Bernardi G, Caltagirone C, Koch G.

Neuropharmacology. 2013 Jan;64:108-13. doi: 10.1016/j.neuropharm.2012.07.015. Epub 2012 Aug 1.

Tamibarotene: a candidate retinoid drug for Alzheimer's disease

Fukasawa H, Nakagomi M, Yamagata N, Katsuki H, Kawahara K, Kitaoka K, Miki T, Shudo K.

Biol Pharm Bull. 2012;35(8):1206-12. doi: 10.1248/bpb.b12-00314.

Vascular cognitive impairment and Alzheimer's disease: role of cerebral hypoperfusion and oxidative stress

Kim HA, Miller AA, Drummond GR, Thrift AG, Arumugam TV, Phan TG, Srikanth VK, Sobey CG.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):953-9. doi: 10.1007/s00210-012-0790-7. Epub 2012 Aug 8.

Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics

Lachno DR, Emerson JK, Vanderstichele H, Gonzales C, Martényi F, Konrad RJ, Talbot JA, Lowe SL, Oefinger PE, Dean RA.

J Alzheimers Dis. 2012;32(4):905-18. doi: 10.3233/JAD-2012-121075.

What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research

Salkovic-Petrisic M, Knezovic A, Hoyer S, Riederer P.

J Neural Transm (Vienna). 2013 Jan;120(1):233-52. doi: 10.1007/s00702-012-0877-9. Epub 2012 Aug 12.

Towards a bioinformatics analysis of anti-Alzheimer's herbal medicines from a target network perspective

Sun Y, Zhu R, Ye H, Tang K, Zhao J, Chen Y, Liu Q, Cao Z.

Brief Bioinform. 2013 May;14(3):327-43. doi: 10.1093/bib/bbs025. Epub 2012 Aug 11.

Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?

Teich AF, Arancio O.

Biochem J. 2012 Sep 1;446(2):165-77. doi: 10.1042/BJ20120653.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias